MTOR and cardiac hypertrophy: Several in vivo and in vitro studies have documented that the mTOR pathway is a promising therapeutic target for pressure overload-, isoproterenol (ISO)- and angiotensin (Ang) II-induced cardiac hypertrophy, and fibrosis (, , 68).